We use cookies for a better user experience. Read our Privacy Policy

I Agree

Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market (Type: Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others; Route of Administration: Intratumoral and Intravenous; and Application: Melanoma, Non-small Cell Lung Cancer [NSCLC], Pancreatic Cancer, Breast Cancer, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Oncolytic Virus Immunotherapy Spearheads Developments in Modern Oncology

Due to advancements in medical science and technology, at present, immunotherapy is at the helm of modern oncology care due to which, the deployment of oncolytic virus immunotherapy has witnessed consistent growth. A spectrum of immunotherapies that primarily target three major layers of tumor biology, including immune system, niche, and tumor has gained considerable traction due to promising end-results. Oncolytic virus immunotherapy is an emerging primary as well as salvage therapy around the world and as per current observations, the trend is likely to continue during the forecast period.

Over the past couple of decades, the development of anti-cancer treatment therapies has largely been focused on delivering customized therapy to cellular targets. The promising outcomes during the early stage clinical trials with oncolytic virus immunotherapy are another factor expected to play an imperative role in boosting the overall growth of the oncolytic virus immunotherapy market in the upcoming decade. Research and development activities, increasing collaborations between research institutes and medical colleges, and rising number of cancer patients around the world are some of the primary factors that are expected to drive the global oncolytic virus immunotherapy market during the assessment period.

At the back of these factors, the global oncolytic virus immunotherapy market is expected to cross a market value of ~US$ 2.3 Bn by the end of 2030.

Request a sample to get extensive insights into the Oncolytic Virus Immunotherapy Market

FDA Approval Key to Boost Market Growth

While research and development activities are likely to shift gears during the course of the forecast period, approval from the FDA for various oncolytic virus immunotherapies is projected to drive the oncolytic virus immunotherapy market. In the current scenario, a number of oncolytic viruses are in the pre-clinical and the clinical development stage. In addition, current findings of research indicate that the therapeutic potential of oncolyitc viruses extend beyond melanomas. Over the past decade, oncolytic virus immunotherapy has garnered immense popularity as a novel development in the field of cancer therapies and the trend is set to continue during the forecast period. In addition, oncolytic virus immunotherapy address the underlying challenges associated with traditional therapies, including radiotherapy and chemotherapy due to which, the demand for oncolytic virus immunotherapy has increased worldwide. Oncolytic viruses are likely to influence oncologic care as therapeutic adjuvant– another factor that is projected to propel the demand for oncolytic virus immunotherapy during the forecast period. Moreover, oncolytic virus immunotherapies are likely to address the primary issue of acquired and primary immunotherapeutic resistance.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Research and Development Activities Likely to Gain Considerable Traction

The oncolytic virus immunotherapy is anticipated to revolutionize the future of cancer treatment. A number of oncolytic virus immunotherapies are in the development phase and likely to hit the oncolytic virus immunotherapy market over the course of the forecast period. Translational and clinical efforts that leverage the findings of research and development activities to curate effective oncolytic virus immunotherapies for cancer patients have gained worldwide popularity in the past few years– a factor that is expected to propel market growth during the assessment period. A number of oncolytic virus platforms are being evaluated in clinical trials, including Adenovirus, Piconavirus, Maraba virus, Reovirus, and Vaccinia virus, among others. While the evaluation of these oncolytic virus platforms continues, the development of new platforms and approaches continues to take shape and offer promise due to which, the prospects of the global oncolytic virus immunotherapy market look bright in the upcoming years. Researchers are also exploring the potential of effective combination immunotherapy by utilizing oncolytic viruses to accurately delivery of chimeric antigen receptor (CAR) targets to solid tumor.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Oncolytic Virus Immunotherapy Market

Demand to Remain Steady amid COVID-19 Pandemic

The advent of the COVID-19 pandemic is expected to have insignificant impact on the overall growth prospects of the global oncolytic virus immunotherapy market. Research and development activities continue to gain notable traction as researchers continue to explore the possibilities of using oncolytic virus immunotherapy tools to curb the transmission of COVID-19 infection. The COVID-19 pandemic has resulted in a dire need for the development of an effective vaccine against the novel coronavirus due to which, research activities are on the rise.

Analysts’ Viewpoint

The global oncolytic virus immunotherapy market is expected to expand at a staggering CAGR of ~32% during the forecast period. The market growth can be primarily attributed to rising prevalence of cancer worldwide, research and development activities, technological advancements, and increasing collaborations between market players and research institutes. At present, market players should focus on exploring the potential benefits of using oncolytic virus immunotherapy tools to contain the spread of the novel coronavirus.

Oncolytic Virus Immunotherapy Market: Overview

  • According to Transparency Market Research’s latest report on the global oncolytic virus immunotherapy market for the historical period 2018–2019 and forecast period 2020–20230, promising pipeline is projected to drive the global oncolytic virus immunotherapy market
  • Oncolytic viruses are a form of immunotherapy, which uses viruses to infect and destroy cancer cells. Oncolytic viruses are genetically modified to target specific types of cancer cells. These replicate within the cancer cell via a tumor-specific promoter element that is incorporated into the viral genome or in deletions in key portions of the viral genome.

Rise in Prevalence of Cancer to Drive Oncolytic Virus Immunotherapy Market

  • Change in lifestyle and dietary habits are risk factors for cancer. Moreover, environmental factors such as asbestos fibers, polynuclear hydrocarbons, metal compounds, and plastic chemicals cause cancer. Hence, increase in burden due to abovementioned factors, population growth, and the changing prevalence of certain causes of cancer linked to social and economic development are expected to boost the growth of the global oncolytic virus immunotherapy market. According to the World Health Organization, in 2018, an estimated 18.1 million new cases of cancer and 9.6 million deaths were reported across the globe.

Focus on Research & Development Propels Oncolytic Virus Immunotherapy Market

  • Rise in prevalence of cancer leads to increase in demand for newer therapeutics. Hence, key players operating in market are engaged in developing new products and focus on research & development to introduce new products with advanced technologies. For instance, Oncolys BioPharma, Inc. announced the phase 1 study for Telomelysin (OBP-301) of hepatocellular carcinoma (HCC) in South Korea and Taiwan in 2020.
  • The development of oncolytic viruses as cancer treatment is moving rapidly. A wide array of viruses are being developed for some of the toughest cancers. This is likely to fuel the growth of the global market.

Limitations of Oncolytic Virus Therapy to Hamper Oncolytic Virus Immunotherapy Market

  • A number of oncolytic viruses are currently under clinical development. Each oncolytic virus carries the characteristics of the parental wild type virus, not only the advantages, but also the disadvantages. One major concern of oncolytic virus therapy has been that the efficacy may be diminished by the presence of circulating antibodies. Moreover, relative poor intratumoral penetration by the oncolytic viruses, which were modified to have a reduced replicative potential, is one of the major limitations of oncolytic virus. This hampers the growth of market.

Oncolytic Virus Immunotherapy Market: Competition Landscape

  • This report profiles major players operating in the global oncolytic virus immunotherapy market based on various attributes and recent developments
  • The global oncolytic virus immunotherapy market is highly fragmented, with the presence of a number of global as well as regional players
  • Leading players operating in the global oncolytic virus immunotherapy market include
    • Amgen, Inc.
    • Merck & Co., Inc. (Viralytics Limited)
    • Shanghai Sunway Biotech Co., Ltd.
    • TILT Biotherapeutics
    • Oncorus, Inc.
    • Replimune Group, Inc.
    • Oncolys BioPharma, Inc.
    • Sorrento Therapeutics, Inc.
    • Oncolytics Biotech, Inc.
    •  SillaJen, Inc.

Oncolytic Virus Immunotherapy Market: Key Developments

  • Key players in the global oncolytic virus immunotherapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at addressing unmet needs in the oncolytic virus immunotherapy market, strengthening the product portfolio, and investing in research & development. Listed below are a few expansion strategies adopted by players operating in the global oncolytic virus immunotherapy market.
  • In July 2020, Oncorus, Inc. announced the clinical trial collaboration agreement with Merck to evaluate the combination of Oncorus’ ONCR-177 with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab)
  • Oncolys BioPharma, Inc. received the notice of orphan drug designation of Telomelysin (OBP-301) oncolytic viral immunotherapy for treatment of esophageal cancer from FDA in June 2020
  • In June 2019, TILT Biotherapeutics entered into an agreement with Merck KGaA and Pfizer to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities
  • In February 2018, Viralytics Limited announced the acquisition agreement with Merck & Co., Inc. This enabled Merck to expand its leading immuno-oncology pipeline.
  • The report on the global oncolytic virus immunotherapy market discusses individual strategies, followed by company profiles of manufacturers of oncolytic viruses. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global oncolytic virus immunotherapy market.

Oncolytic Virus Immunotherapy Market – Segmentation

Type

  • Herpes Simplex Virus
  • Vaccinia Virus
  • Adenovirus
  • Reovirus
  • Others

Route of Administration

  • Intratumoral
  • Intravenous

Application

  • Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Pancreatic Cancer
  • Breast Cancer
  • Others

Region

  • North America
  • Europe
  • APAC
  • Rest of the World
Oncolytic Virus Immunotherapy Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of oncolytic virus immunotherapy market?

Oncolytic virus immunotherapy market to cross valuation of US$ 2.3 Bn by 2030

What is the anticipated CAGR of the oncolytic virus immunotherapy market in the forecast period?

Oncolytic virus immunotherapy market is projected to expand at a CAGR of ~32% from 2020 to 2030

What are the key driving factors for the growth of the oncolytic virus immunotherapy market?

Oncolytic virus immunotherapy market is driven by rising number of cancer patients around the world

Which region is expected to project the highest market share in the global oncolytic virus immunotherapy market?

North America accounted for a major share of the global oncolytic virus immunotherapy market, the trend is anticipated to continue during the forecast period

Who are the key players in the global oncolytic virus immunotherapy market?

Key players in the global oncolytic virus immunotherapy market include Amgen, Inc., Merck & Co., Inc. (Viralytics Limited), Shanghai Sunway Biotech Co.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2018–2030

5. Key Insights

    5.1. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    5.2. Pipeline Analysis

    5.3. Key Industry Developments

    5.4. Features of oncolytic viruses

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

        6.3.1. Herpes Simplex Virus

        6.3.2. Vaccinia Virus

        6.3.3. Adenovirus

        6.3.4. Reovirus

        6.3.5. Others

    6.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

        7.3.1. Intratumoral

        7.3.2. Intravenous

    7.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

        8.3.1. Melanoma

        8.3.2. Non-small Cell Lung Cancer (NSCLC)

        8.3.3. Pancreatic Cancer

        8.3.4. Breast Cancer

        8.3.5. Others

    8.4. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Oncolytic Virus Immunotherapy Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Rest of World

    9.3. Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

        10.2.1. Herpes Simplex Virus

        10.2.2. Vaccinia Virus

        10.2.3. Adenovirus

        10.2.4. Reovirus

        10.2.5. Others

    10.3. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

        10.3.1. Intratumoral

        10.3.2. Intravenous

    10.4. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

        10.4.1. Melanoma

        10.4.2. Non-small Cell Lung Cancer (NSCLC)

        10.4.3. Pancreatic Cancer

        10.4.4. Breast Cancer

        10.4.5. Others

    10.5. North America Oncolytic Virus Immunotherapy Market Value Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Route of Administration

        10.6.3. By Application

        10.6.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

        11.2.1. Herpes Simplex Virus

        11.2.2. Vaccinia Virus

        11.2.3. Adenovirus

        11.2.4. Reovirus

        11.2.5. Others

    11.3. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

        11.3.1. Intratumoral

        11.3.2. Intravenous

    11.4. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

        11.4.1. Melanoma

        11.4.2. Non-small Cell Lung Cancer (NSCLC)

        11.4.3. Pancreatic Cancer

        11.4.4. Breast Cancer

        11.4.5. Others

    11.5. Europe Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Route of Administration

        11.6.3. By Application

        11.6.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

        12.2.1. Herpes Simplex Virus

        12.2.2. Vaccinia Virus

        12.2.3. Adenovirus

        12.2.4. Reovirus

        12.2.5. Others

    12.3. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

        12.3.1. Intratumoral

        12.3.2. Intravenous

    12.4. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

        12.4.1. Melanoma

        12.4.2. Non-small Cell Lung Cancer (NSCLC)

        12.4.3. Pancreatic Cancer

        12.4.4. Breast Cancer

        12.4.5. Others

    12.5. Asia Pacific Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Route of Administration

        12.6.3. By Application

        12.6.4. By Country/Sub-region

13. Rest of World Oncolytic Virus Immunotherapy Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Type, 2018–2030

        13.2.1. Herpes Simplex Virus

        13.2.2. Vaccinia Virus

        13.2.3. Adenovirus

        13.2.4. Reovirus

        13.2.5. Others

    13.3. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Route of Administration, 2018–2030

        13.3.1. Intratumoral

        13.3.2. Intravenous

    13.4. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Application, 2018–2030

        13.4.1. Melanoma

        13.4.2. Non-small Cell Lung Cancer (NSCLC)

        13.4.3. Pancreatic Cancer

        13.4.4. Breast Cancer

        13.4.5. Others

    13.5. Rest of World Oncolytic Virus Immunotherapy Market Value Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Route of Administration

        13.6.3. By Application

        13.6.4. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis/Ranking, by Company, 2019

    14.3. Company Profiles

        14.3.1. Amgen Inc.

            14.3.1.1. Company Overview

            14.3.1.2. Company Financials

            14.3.1.3. Growth Strategies

            14.3.1.4. SWOT Analysis

        14.3.2. Merck & Co., Inc. (Viralytics Limited)

            14.3.2.1. Company Overview

            14.3.2.2. Company Financials

            14.3.2.3. Growth Strategies

            14.3.2.4. SWOT Analysis

        14.3.3. Shanghai Sunway Biotech Co., Ltd

            14.3.3.1. Company Overview

            14.3.3.2. Growth Strategies

            14.3.3.3. SWOT Analysis

        14.3.4. TILT Biotherapeutics

            14.3.4.1. Company Overview

            14.3.4.2. Growth Strategies

            14.3.4.3. SWOT Analysis

        14.3.5. Oncorus, Inc.

            14.3.5.1. Company Overview

            14.3.5.2. Growth Strategies

            14.3.5.3. SWOT Analysis

        14.3.6. Replimune Group, Inc.

            14.3.6.1. Company Overview

            14.3.6.2. Company Financials

            14.3.6.3. Growth Strategies

            14.3.6.4. SWOT Analysis

        14.3.7. Oncolys BioPharma, Inc.

            14.3.7.1. Company Overview

            14.3.7.2. Company Financials

            14.3.7.3. Growth Strategies

            14.3.7.4. SWOT Analysis

        14.3.8. Sorrento Therapeutics, Inc.

            14.3.8.1. Company Overview

            14.3.8.2. Company Financials

            14.3.8.3. Growth Strategies

            14.3.8.4. SWOT Analysis

        14.3.9. Oncolytics Biotech, Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Company Financials

            14.3.9.3. Growth Strategies

            14.3.9.4. SWOT Analysis

        14.3.10. SillaJen, Inc.

            14.3.10.1. Company Overview

            14.3.10.2. Growth Strategies

            14.3.10.3. SWOT Analysis

List of Table

Table 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 02: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 03: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Type, 2018–2030

Table 04: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country, 2018–2030

Table 06: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 07: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 08: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 09: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 11: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 12: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

Table 17: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Type, 2018–2030

Table 18: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Route of Administration, 2018–2030

Table 19: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast, by Application, 2018–2030

List of Figure

Figure 01: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2019

Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2019

Figure 04: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2019

Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2019

Figure 06: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2019 and 2030

Figure 07: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 08: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Herpes Simplex Virus, 2018–2030

Figure 09: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Vaccinia Virus, 2018–2030

Figure 10: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Adenovirus, 2018–2030

Figure 11: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Reovirus, 2018–2030

Figure 12: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030

Figure 13: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2019 and 2030

Figure 14: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 15: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intratumoral, 2018–2030

Figure 16: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Intravenous, 2018–2030

Figure 17: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2019 and 2030

Figure 18: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 19: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Melanoma, 2018–2030

Figure 20: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Non-small Cell Lung Cancer (NSCLC), 2018–2030

Figure 21: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Pancreatic Cancer, 2018–2030

Figure 22: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Breast Cancer, 2018–2030

Figure 23: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Others, 2018–2030

Figure 24: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2019 and 2030

Figure 25: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region

Figure 26: North America Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 27: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Country, 2019 and 2030

Figure 28: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2020–2030

Figure 29: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 30: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 31: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 32: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 33: North America Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 34: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 35: Europe Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 36: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 37: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 38: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 39: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 40: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 41: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 42: Europe Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 43: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 45: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Country/Sub-region, 2019 and 2030

Figure 46: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 47: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2019 and 2030

Figure 48: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2020–2030

Figure 49: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2019 and 2030

Figure 50: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2020–2030

Figure 51: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2019 and 2030

Figure 52: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2020–2030

Figure 53: Rest of World Oncolytic Virus Immunotherapy Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 54: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Type, 2021 and 2030

Figure 55: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2022–2030

Figure 56: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Route of Administration, 2021 and 2030

Figure 57: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2022–2030

Figure 58: Rest of World Oncolytic Virus Immunotherapy Market Value Share (%), by Application, 2021 and 2030

Figure 59: Rest of World Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022–2030

Figure 60: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 61: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 62: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 63: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 64: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 65: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2019

Figure 66: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 67: Replimune Group, Inc. Total Operating Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2020

Figure 68: Replimune Group, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2019

Figure 69: Oncolys BioPharma, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 70: Oncolys BioPharma, Inc. Breakdown of Net Sales (%), by Region/Country, 2019

Figure 71: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 72: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2019

Figure 73: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2019

Figure 74: Oncolytics Biotech, Inc. Total assets (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Figure 75: Oncolytics Biotech, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2019

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

188

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved